Skip to Content

Taltz Approval History

FDA Approved: Yes (First approved March 22, 2016)
Brand name: Taltz
Generic name: ixekizumab
Dosage form: Injection
Company: Eli Lilly and Company
Treatment for: Plaque Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis

Taltz (ixekizumab) is a humanized interleukin-17A antagonist indicated for the treatment of plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis.

Development History and FDA Approval Process for Taltz

Aug 26, 2019Approval FDA Approves Taltz (ixekizumab) for the Treatment of Active Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis)
May 22, 2018Approval Lilly's Taltz (ixekizumab) Receives the First U.S. FDA Approval for Label Update to Include Data for Psoriasis Involving the Genital Area
Dec  1, 2017Approval Lilly's Taltz (ixekizumab) Receives U.S. FDA Approval for the Treatment of Active Psoriatic Arthritis
Mar 22, 2016Approval FDA Approves Taltz (ixekizumab) for Plaque Psoriasis
Mar  4, 2016Ixekizumab Demonstrates Rapid, Clinically Meaningful Improvements As Early As One Week Among Patients With Moderate-To-Severe Plaque Psoriasis
Nov  8, 2015Patients Show Significant Improvement In Signs And Symptoms Of Psoriatic Arthritis, Less Progression Of Structural Joint Damage When Treated With Ixekizumab For 24 Weeks
Jun 10, 2015Studies Show Psoriasis Patients Achieved Significant Levels Of Skin Clearance And Improved Quality Of Life After 12 Weeks Of Ixekizumab Treatment
Aug 21, 2014Lilly's Ixekizumab Superior to Etanercept and Placebo in Phase 3 Psoriasis Studies

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.